*Last Years Meeting Agenda* 

ONA/OHA 

 Annual Educational Conference

May 13-14, 2011

New Albany Surgical Hospital Foundation

New Albany, Ohio

 Agenda

Day 1 Ohio Headache Association:  Focus on Chronic Migraine

12:00 Lunch and Registration

1:00- 1:15 Welcome and Introductions: Vincent Martin, MD

1:15 Dx, Epidemiology and Risk Factors for Chronic Migraine: Frank O’Donnell, DO

1:45 Pathophysiology of Chronic Migraine: Stew Tepper, MD

2:15 Abortive and Preventative Treatment of Chronic Migraine: Mark Stillman, MD

2:45 Break

3:00 Cervicogenic Headaches:             Wade Cooper, MD

3:30 Medication Overuse Headaches:   Glenn Solomon, MD

4:00 Hemicrania Continua: Rod Spears, MD

4:30 Break

4:45 Comorbid Medical Illnesses and Chronic Migraine: Gretchen Tietjen, MD

5:15 Joint Hypermobility Syndrome: A Common Clinical Disorder Associated with Migraine in Women: Vincent Martin, MD

6:00 Panel Discussion

6:15 Keynote Lecture; Botulinum Toxin Therapy for Chronic Migraine:             Sheena Aurora, MD

7:00 Headache Injection Demonstration (BTX, ONB): Martin Taylor, DO, PhD/ Lisa Mannix, MD

Day 2 Ohio Neurotoxin Association: Botulinum Toxin Therapy for the Treatment of Pain

8:15 Welcome and Introductions:        Martin Taylor, DO, PhD

8:30 Scientific Update: David Riley, MD

9:00 Facial Pain and Bruxism:              Jeffrey Okeson, DMD

9:30 Ultrasound Guidance for Pain Injections: Katharine Alter, MD

Break

10:15 Extremity Pain: Jeff Gittins, DO

10:45 Neck and Back Pain:                  Martin Childers, DO, PhD

11:30 Neuropathic Pain: Micheal Jones, DO

12:00 Working Lunch:  Billing and Coding Update: Martin Taylor, DO, PhD

1:00-4:00  Rotating Injection Sessions

Low Back/Piriformis Pain: David Riley, MD/ Jeff Gittins, DO

Head , Upper Back, and  Neck pain: MaryAnn Mays, MD/Desmond Stutzman, DO

Accreditation

This program has been submitted for 7 category 1-A credits from the American Osteopathic Association.

 FOR PURPOSES OF RELICENSURE ONLY, the State Medical Board of Ohio has determined that allopathic physicians may claim AMA PRA Category 1 credit for attending CME programs which are acceptable for AOA Category 1-A credit, as outlined in the American Osteopathic Association (AOA) and the Ohio Osteopathic Association (OOA) CME program.

Learning Objectives

After completing this program, participants should be able to:

• Understand the mechanism of action and the conceptual basis for therapeutic BoNTs in a broad array of clinical conditions
• Review a range of clinical application in which BoNT has been shown to have an effect
• Increase their knowledge of the spectrum of treatments and interventions for these disorders and understand where BoNTs fit into the treatment regimen
• Identify appropriate patients for therapy and determine condition-specific techniques, including injection-site-specific selection and dosing of BoNT
• Understand key considerations involved in establishing treatment plans, including diagnosis and baseline assessment of the patient, recognition of specific symptoms and co-morbidities, and establishment of appropriate expectations for treatment outcomes
• Discuss procedures for administering BoNT therapy
• Recognize the importance of post-injection follow-up and outcomes assessment